ClinicalTrials.gg
RecruitingNCT07511582CHIPUpdated Nov 18, 2026

Corticosteroids in Hyperinflammatory Phenotype of Critical Illness

A Phase 2 interventional study of Methylprednisolone (MP) and Methylprednisolone (MP) in Sepsis and Acute Respiratory Distress Syndrome, sponsored by Bin Du. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Bin Du · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 18, 2026Eligibility revised10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.

Planned enrollment
53rd of 121
150 · median 118
Started
2026
with 32 others
Phase 2
12 of 286
4 open now
Primary completion
2028-04
later than 88 of 105 live
Registered
257th of 286
by date

Among the 286 studies in Sepsis with a site in China, this one is the 53rd largest by planned enrollment of the 121 interventional ones that give a count, is one of 33 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 88 of the 105 other live ones, and was the 257th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:

93 more — sign in →

All 99 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Sepsis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether methylprednisolone improves outcomes in critically ill patients with a hyperinflammatory phenotype. It will also evaluate the safety of methylprednisolone at different doses.

The main questions it aims to answer are:

  • Does methylprednisolone improve organ function compared with placebo?
  • Does methylprednisolone reduce the risk of mortality within 30 days?

Researchers will compare high-dose methylprednisolone (160mg/d), low-dose methylprednisolone (80mg/d), and placebo (normal saline) to evaluate effectiveness and safety.

Participants will:

  • Receive high-dose methylprednisolone, low-dose methylprednisolone, or placebo every 12 hours for the first 3 days
  • Be reassessed on Day 4 based on their inflammatory status If the hyperinflammatory phenotype persists, the treatment dose will be reduced by half and continued until Day 7 or ICU discharge, whichever occurs first If the patient transitions to a hypoinflammatory phenotype, the study treatment will be discontinued
  • Be monitored daily in the intensive care unit for organ function, inflammatory status, and need for organ support
  • Be followed for up to 30 days after randomization to assess survival and recovery
Read the detailed description

Background: Acute respiratory distress syndrome (ARDS) and sepsis are common critical illnesses associated with persistently high mortality. The lack of improvement in overall outcomes despite multiple interventions may be attributable to substantial biological heterogeneity. Both ARDS and sepsis can be classified into hyperinflammatory and hypoinflammatory phenotypes based on clinical variables and/or biomarkers. Previous retrospective and target trial emulation studies suggest differential treatment responses, with hyperinflammatory patients potentially benefiting from corticosteroid therapy.

Objective: The primary objective is to evaluate the preliminary efficacy signal of intravenous methylprednisolone, compared with placebo, in critically ill patients with a hyperinflammatory phenotype. The primary endpoint is the proportion of patients achieving a ≥1.4-point reduction in mean Sequential Organ Failure Assessment (SOFA) score from baseline to Day 9. Secondary objectives include evaluation of 30-day mortality, organ support-free days, safety, and tolerability, and to inform endpoint selection and dose optimization for a future phase III trial.

Study Design: This is a multicenter, randomized, double-blind, placebo-controlled phase II trial. Participants will be randomized using a centralized system with stratified permuted block randomization by study site, with varying block sizes to minimize predictability. Eligible participants will be assigned in a 1:1:1 ratio to high-dose methylprednisolone, low-dose methylprednisolone, or placebo.

Participants:

Inclusion Criteria: Participants must meet all of the following criteria:

① Age ≥18 years; ② Onset of ARDS and/or sepsis within 72 hours.

  • ARDS is defined according to the Berlin definition: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by pleural effusions, lobar or lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload; and PaO2/FiO2 ≤ 300 mmHg with PEEP ≥ 5 cm H2O.
  • Sepsis is defined according to Sepsis-3 as suspected or confirmed infection accompanied by an acute increase in SOFA score of ≥ 2 points attributable to infection.③ Requirement for invasive mechanical ventilation; ④ Hyperinflammatory phenotype, defined as a predicted probability ≥ 0.50 using the clinical classifier; ⑤ Written informed consent from patient or legally authorized representative.

Exclusion Criteria: Participants meeting any of the following will be excluded:

① High-dose vasopressor requirement, defined as a norepinephrine-equivalent dose (NEE) ≥ 0.25 μg/kg/min; ② Systemic corticosteroid exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any immunosuppressive agent within the same period; ③ Solid-organ transplantation or allogeneic stem-cell transplantation; ④ Severe congenital or acquired immunodeficiency, including HIV infection; ⑤ Brain death, expected death within 24 hours, or advanced malignancy or other end-stage disease with a life expectancy of less than 6 months; ⑥ A do-not-resuscitate order or a decision to withdraw or withhold life-sustaining treatment; ⑦ Life-threatening active fungal infection or active tuberculosis; ⑧Known hypersensitivity to corticosteroids; ⑨Pregnancy or lactation; ⑩ Neuromuscular disease that substantially impairs spontaneous breathing; ⑪ Concurrent participation in another interventional clinical trial; ⑫ Any other clinical condition that, in the opinion of the treating physician or investigator, makes participation inappropriate.

Sample Size: This phase II exploratory trial aims to estimate clinically meaningful effect sizes rather than formally test hypotheses. A total of 150 participants (50 per group) will be enrolled. Assuming a 10% dropout rate, approximately 45 evaluable participants per group are expected. In the published ImmunoSep randomised clinical trial, the primary endpoint-a reduction of at least 1.4 points in mean SOFA score from baseline to days 2-9-was achieved by 35.1% of participants receiving precision immunotherapy and 17.9% receiving placebo, corresponding to an absolute difference of 17.2 percentage points (95% CI 6.8 to 27.2).Using these observed proportions as illustrative assumptions, 45 evaluable participants per group would yield an approximate half-width of 17.9 percentage points for the 95% CI of the absolute difference between an active-dose group and placebo. The sample size is therefore intended to provide preliminary estimates of treatment effects and their uncertainty, while supporting the selection of outcomes and sample-size planning for a future phase III trial.

Interventions: Participants will be randomized to: High-dose group: methylprednisolone 80 mg IV every 12 hours; Low-dose group: methylprednisolone 40 mg IV every 12 hours; or Placebo group: normal saline (100 mL) IV every 12 hours. All treatments will be identical in volume, appearance, and administration. At Day 4, inflammatory phenotype will be reassessed; treatment will be discontinued if phenotype transitions to hypoinflammatory. Otherwise, dose will be halved and continued until Day 7 or ICU discharge. All patients will receive standard ICU care according to guidelines.

Blinding: Double-blind design. Drug preparation will be performed by unblinded personnel, while investigators, clinicians, and patients remain blinded.

Outcomes: Primary outcome is proportion of patients achieving a ≥1.4-point reduction in mean SOFA score from baseline to Day 9. Mean SOFA change is calculated as baseline SOFA minus the average SOFA from Days 2-9. For patients who die before Day 9, SOFA is imputed as 24 thereafter; for discharged patients, last observation carried forward (LOCF) is applied. Secondary outcomes include 30-day all-cause mortality, 30-day organ support-free days (OSFD) and Incidence and severity of adverse events. Exploratory outcomes include ICU and hospital length of stay; ventilator-, vasopressor-, and RRT-free days; phenotype transition rates; biomarkers (CRP, PCT, IL-6, etc.); SOFA score trajectory; Vasoactive-Inotropic Score (VIS); incidence of new infections Statistical Analysis: Analyses will follow the intention-to-treat principle. Primary outcome will be reported as proportions with risk differences and 95% confidence intervals. Secondary and exploratory outcomes will be analyzed descriptively. Results will inform effect size estimation and design of a future phase III trial.

03

Conditions studied

  • Sepsis
  • Acute Respiratory Distress Syndrome

Keywords

  • Corticosteroids
  • Hyperinflammatory phenotype
  • Sepsis
  • Acute respiratory distress syndrome
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Onset of ARDS and/or sepsis within 72 hours.

    • ARDS is defined according to the Berlin definition: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by pleural effusions, lobar or lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload; and PaO2/FiO2 ≤300 mmHg with PEEP ≥ 5 cm H2O.
    • Sepsis is defined according to Sepsis-3 as suspected or confirmed infection accompanied by an acute increase in SOFA score of ≥ 2 points attributable to infection.
  3. Requirement for invasive mechanical ventilation.
  4. Hyperinflammatory phenotype, defined as a predicted probability ≥ 0.50 using the clinical classifier.
  5. Written provided by the participant or a legally authorised representative.

Exclusion criteria

Exclusion criteria

  1. High vasopressor requirement, defined as a norepinephrine-equivalent dose (NEE) ≥ 0.25 μg/kg/min.
  2. Systemic exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any agent within the same period.[16]
  3. Solid-organ transplantation or stem-cell transplantation.
  4. Severe congenital or acquired immunodeficiency, including infection.
  5. Brain death, expected death within 24 hours, or advanced or other end-stage disease with a of less than 6 months.
  6. A do-not-resuscitate order or a decision to withdraw or withhold life-sustaining treatment.
  7. Life-threatening active fungal infection or active tuberculosis.
  8. Known to corticosteroids.
  9. Pregnancy or lactation.
  10. Neuromuscular disease that substantially impairs spontaneous breathing.
  11. Concurrent participation in another interventional clinical trial.
  12. Any other clinical condition that, in the opinion of the treating physician or investigator, makes participation inappropriate.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    high dose methylprednisolone group

    Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

    Drug: Methylprednisolone (MP)

  • Experimental
    low dose methylprednisolone group

    Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

    Drug: Methylprednisolone (MP)

  • Placebo comparator
    placebo group

    Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

    Drug: Placebo

Interventions

  • DrugMethylprednisoloneStudies of MethylprednisoloneMethylprednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

  • DrugMethylprednisoloneStudies of MethylprednisoloneMethylprednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

  • DrugPlacebo

    Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with a decrease in mean Sequential Organ Failure Assessment (SOFA) score ≥1.4 points from baseline to Day 9

    The outcome is defined as the proportion of patients achieving a decrease of ≥1.4 points in mean SOFA score from baseline to Day 9. The mean change in SOFA score is calculated as the baseline SOFA score (Day 1) minus the average SOFA score from Days 2 through 9.The lowest possible SOFA score is 0, and the highest is 24. The higher the score, the more severe the organ dysfunction.

    Time frame: From baseline (Day 1) to Day 9

Secondary outcomes

  1. 30-day Organ Support Free Days (OSFD)

    Organ Support Free Days (OSFD) is defined as the number of days within 30 days where the patient survives without the need for any organ support, including respiratory support (mechanical ventilation and extracorporeal membrane oxygenation \[ECMO\]), circulatory support (vasopressors, positive inotropic agents, intra-aortic balloon pump \[IABP\], and ECMO), and renal replacement therapy. If the patient dies within 30 days, OSFD is recorded as 0 days.

    Time frame: From randomization to 30 days

  2. 30-day mortality

    30-day mortality is defined as death from any cause within 30 days after randomization.

    Time frame: From randomization to 30 days

  3. Incidence and severity of adverse events and serious adverse events during treatment

    The outcome includes the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during the treatment period. Adverse events of interest include hyperglycemia (requiring insulin therapy in non-diabetic patients or increased insulin dosage in diabetic patients), gastrointestinal bleeding, muscle weakness, barotrauma (including pneumothorax, pneumomediastinum, subcutaneous emphysema, or imaging-confirmed findings), new-onset infection (hospital-acquired infections as determined by the treating physician), respiratory acidosis, severe acidosis (pH \< 7.10), refractory hypoxemia (PaO₂ \< 55 mmHg), severe hypotension (mean arterial pressure \< 60 mmHg), new-onset arrhythmia (including atrial fibrillation or supraventricular tachycardia), cardiac arrest, and all reported serious adverse events.

    Time frame: During the treatment period (from randomization to Day 7 or ICU discharge, whichever occurs first)

Other outcomes

  1. Length of ICU stay

    Length of ICU stay is defined as the time from randomization to ICU discharge. Patients who remain in the ICU at 30 days after randomization or die during ICU stay will be assigned a value of 30 days.

    Time frame: From randomization to 30 days

  2. Length of hospital stay

    Length of hospital stay is defined as the time from randomization to hospital discharge. Patients who remain hospitalized at 30 days after randomization or die during hospitalization will be assigned a value of 30 days.

    Time frame: From randomization to 30 days

  3. 30-day ventilator-free days (VFD)

    Ventilator-free days (VFD) are defined as the number of days from successful extubation to 30 days after randomization. Successful extubation is defined as liberation from mechanical ventilation for at least 48 hours without reintubation. Patients who remain ventilated at 30 days or die within 30 days will be assigned 0 ventilator-free days.

    Time frame: From randomization to 30 days

  4. 30-day vasopressor-free days

    Vasopressor-free days are defined as the number of days from the last discontinuation of circulatory support to 30 days after randomization. Circulatory support includes vasopressors, inotropic agents, intra-aortic balloon pump (IABP), and extracorporeal membrane oxygenation (ECMO). Discontinuation is defined as cessation of vasopressors and inotropes for at least 48 hours without reinitiation. Patients who remain on circulatory support at 30 days or die within 30 days will be assigned 0 vasopressor-free days.

    Time frame: From randomization to 30 days

  5. 30-day renal replacement therapy-free days

    Renal replacement therapy (RRT)-free days are defined as the number of days from the last discontinuation of RRT to 30 days after randomization. Discontinuation is defined as cessation of RRT for at least 48 hours without reinitiation. Patients who remain on RRT at 30 days or die within 30 days will be assigned 0 RRT-free days.

    Time frame: From randomization to 30 days

  6. Probability of transition from hyperinflammatory to hypoinflammatory phenotype

    The probability of transition from hyperinflammatory to hypoinflammatory phenotype is assessed at Days 1,4, 7, 9, and 15 after randomization.

    Time frame: At Days 1,4, 7, 9, and 15 after randomization

  7. Biomarker levels after randomization

    Levels of inflammatory biomarkers including C-reactive protein (CRP), procalcitonin (PCT), neutrophil-to-lymphocyte ratio (NLR), interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor-alpha (TNF-α), protein C, soluble tumor necrosis factor receptor 1 (sTNFR1), and ferritin.

    Time frame: At Days 1,4, 7, 9, and 15 after randomization

  8. Sequential Organ Failure Assessment (SOFA) score

    SOFA scores are assessed longitudinally to evaluate organ dysfunction over time. The lowest possible SOFA score is 0, and the highest is 24. The higher the score, the more severe the organ dysfunction.

    Time frame: From Day 1 to Day 9 and Day 15 after randomization

  9. Vasoactive-Inotropic Score (VIS)

    VIS is calculated as: dopamine (μg/kg/min) + dobutamine (μg/kg/min) + 10 × milrinone (μg/kg/min) + 100 × epinephrine (μg/kg/min) + 100 × norepinephrine (μg/kg/min) + 10000 × vasopressin (U/kg/min). The minimum VIS score is 0, but there is no fixed maximum score. The higher the score, the greater the dose of vasoactive medications.

    Time frame: At Days 1,4, 7, 9, and 15 after randomization

07

Study locations

11 of 11 sites recruiting
08

References and documents

Publications

  • Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M, Meduri GU. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016 Oct 15;20(1):329. doi: 10.1186/s13054-016-1511-2. PubMed 27741949 ↗
  • Maddali MV, Churpek M, Pham T, Rezoagli E, Zhuo H, Zhao W, He J, Delucchi KL, Wang C, Wickersham N, McNeil JB, Jauregui A, Ke S, Vessel K, Gomez A, Hendrickson CM, Kangelaris KN, Sarma A, Leligdowicz A, Liu KD, Matthay MA, Ware LB, Laffey JG, Bellani G, Calfee CS, Sinha P; LUNG SAFE Investigators and the ESICM Trials Group. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis. Lancet Respir Med. 2022 Apr;10(4):367-377. doi: 10.1016/S2213-2600(21)00461-6. Epub 2022 Jan 10. PubMed 35026177 ↗
  • McNicholas B, Madden MG, Laffey JG. Machine Learning Classifier Models: The Future for Acute Respiratory Distress Syndrome Phenotyping? Am J Respir Crit Care Med. 2020 Oct 1;202(7):919-920. doi: 10.1164/rccm.202006-2388ED. No abstract available. PubMed 32687397 ↗
  • Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22. PubMed 22616830 ↗
  • Pensier J, Fosset M, Paschold BS, von Wedel D, Redaelli S, Braeuer BLP, Novack V, Balzer F, Jung B, Amato MBP, Jaber S, Talmor D, Baedorf-Kassis E, Schaefer MS. Temporal stability of phenotypes of acute respiratory distress syndrome: clinical implications for early corticosteroid therapy and mortality. Intensive Care Med. 2025 Oct;51(10):1784-1796. doi: 10.1007/s00134-025-08089-4. Epub 2025 Aug 21. PubMed 40839098 ↗
  • Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, Calfee CS; ARDS Network. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. Am J Respir Crit Care Med. 2017 Feb 1;195(3):331-338. doi: 10.1164/rccm.201603-0645OC. PubMed 27513822 ↗
  • Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF; Irish Critical Care Trials Group. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018 Sep;6(9):691-698. doi: 10.1016/S2213-2600(18)30177-2. Epub 2018 Aug 2. PubMed 30078618 ↗
  • Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS; NHLBI ARDS Network. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018 Nov;44(11):1859-1869. doi: 10.1007/s00134-018-5378-3. Epub 2018 Oct 5. PubMed 30291376 ↗
  • Sinha P, Kerchberger VE, Willmore A, Chambers J, Zhuo H, Abbott J, Jones C, Wickersham N, Wu N, Neyton L, Langelier CR, Mick E, He J, Jauregui A, Churpek MM, Gomez AD, Hendrickson CM, Kangelaris KN, Sarma A, Leligdowicz A, Delucchi KL, Liu KD, Russell JA, Matthay MA, Walley KR, Ware LB, Calfee CS. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023 Nov;11(11):965-974. doi: 10.1016/S2213-2600(23)00237-0. Epub 2023 Aug 23. PubMed 37633303 ↗
  • National Heart, Lung, and Blood Institute ARDS Clinical Trials Network; Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014 Jun 5;370(23):2191-200. doi: 10.1056/NEJMoa1401520. Epub 2014 May 18. PubMed 24835849 ↗
  • National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006 Jun 15;354(24):2564-75. doi: 10.1056/NEJMoa062200. Epub 2006 May 21. PubMed 16714767 ↗
  • Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004 Jul 22;351(4):327-36. doi: 10.1056/NEJMoa032193. PubMed 15269312 ↗
  • Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS; ARDS Network. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018 May;73(5):439-445. doi: 10.1136/thoraxjnl-2017-211090. Epub 2018 Feb 24. PubMed 29477989 ↗
  • Sinha P, Delucchi KL, Chen Y, Zhuo H, Abbott J, Wang C, Wickersham N, McNeil JB, Jauregui A, Ke S, Vessel K, Gomez A, Hendrickson CM, Kangelaris KN, Sarma A, Leligdowicz A, Liu KD, Matthay MA, Ware LB, Calfee CS. Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study. Thorax. 2022 Jan;77(1):13-21. doi: 10.1136/thoraxjnl-2021-217158. Epub 2021 Jul 12. PubMed 34253679 ↗
  • Rajendran S, Xu Z, Pan W, Zang C, Siempos I, Torres L, Xu J, Bian J, Schenck EJ, Wang F. Multicenter target trial emulation to evaluate corticosteroids for sepsis stratified by predicted organ dysfunction trajectory. Nat Commun. 2025 May 13;16(1):4450. doi: 10.1038/s41467-025-59643-z. PubMed 40360520 ↗
  • Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988 Jul;138(1):62-8. doi: 10.1164/ajrccm/138.1.62. PubMed 3202402 ↗
  • Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987 Sep 10;317(11):653-8. doi: 10.1056/NEJM198709103171101. PubMed 3306374 ↗
  • Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G, Badie J, Francois B, Aubron C, Ricard JD, Ehrmann S, Jouan Y, Guillon A, Leclerc M, Coffre C, Bourgoin H, Lengelle C, Caille-Fenerol C, Tavernier E, Zohar S, Giraudeau B, Annane D, Le Gouge A; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761. PubMed 32876689 ↗
  • Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Goossens H, Green C, Haniffa R, Higgins AM, Horvat C, Hullegie SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley D, McGlothin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sanil A, Santos M, Saunders C, Seymour C, Turner A, van de Veerdonk F, Venkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC; Writing Committee for the REMAP-CAP Investigators; Al-Beidh F, Angus D, Annane D, Arabi Y, van Bentum-Puijk W, Berry S, Beane A, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Rowan K, Seymour C, Turner A, van de Veerdonk F, Webb S, Zarychanski R, Campbell L, Forbes A, Gattas D, Heritier S, Higgins L, Kruger P, Peake S, Presneill J, Seppelt I, Trapani T, Young P, Bagshaw S, Daneman N, Ferguson N, Misak C, Santos M, Hullegie S, Pletz M, Rohde G, Rowan K, Alexander B, Basile K, Girard T, Horvat C, Huang D, Linstrum K, Vates J, Beasley R, Fowler R, McGloughlin S, Morpeth S, Paterson D, Venkatesh B, Uyeki T, Baillie K, Duffy E, Fowler R, Hills T, Orr K, Patanwala A, Tong S, Netea M, Bihari S, Carrier M, Fergusson D, Goligher E, Haidar G, Hunt B, Kumar A, Laffan M, Lawless P, Lother S, McCallum P, Middeldopr S, McQuilten Z, Neal M, Pasi J, Schutgens R, Stanworth S, Turgeon A, Weissman A, Adhikari N, Anstey M, Brant E, de Man A, Lamonagne F, Masse MH, Udy A, Arnold D, Begin P, Charlewood R, Chasse M, Coyne M, Cooper J, Daly J, Gosbell I, Harvala-Simmonds H, Hills T, MacLennan S, Menon D, McDyer J, Pridee N, Roberts D, Shankar-Hari M, Thomas H, Tinmouth A, Triulzi D, Walsh T, Wood E, Calfee C, O'Kane C, Shyamsundar M, Sinha P, Thompson T, Young I, Bihari S, Hodgson C, Laffey J, McAuley D, Orford N, Neto A, Detry M, Fitzgerald M, Lewis R, McGlothlin A, Sanil A, Saunders C, Berry L, Lorenzi E, Miller E, Singh V, Zammit C, van Bentum Puijk W, Bouwman W, Mangindaan Y, Parker L, Peters S, Rietveld I, Raymakers K, Ganpat R, Brillinger N, Markgraf R, Ainscough K, Brickell K, Anjum A, Lane JB, Richards-Belle A, Saull M, Wiley D, Bion J, Connor J, Gates S, Manax V, van der Poll T, Reynolds J, van Beurden M, Effelaar E, Schotsman J, Boyd C, Harland C, Shearer A, Wren J, Clermont G, Garrard W, Kalchthaler K, King A, Ricketts D, Malakoutis S, Marroquin O, Music E, Quinn K, Cate H, Pearson K, Collins J, Hanson J, Williams P, Jackson S, Asghar A, Dyas S, Sutu M, Murphy S, Williamson D, Mguni N, Potter A, Porter D, Goodwin J, Rook C, Harrison S, Williams H, Campbell H, Lomme K, Williamson J, Sheffield J, van't Hoff W, McCracken P, Young M, Board J, Mart E, Knott C, Smith J, Boschert C, Affleck J, Ramanan M, D'Souza R, Pateman K, Shakih A, Cheung W, Kol M, Wong H, Shah A, Wagh A, Simpson J, Duke G, Chan P, Cartner B, Hunter S, Laver R, Shrestha T, Regli A, Pellicano A, McCullough J, Tallott M, Kumar N, Panwar R, Brinkerhoff G, Koppen C, Cazzola F, Brain M, Mineall S, Fischer R, Biradar V, Soar N, White H, Estensen K, Morrison L, Smith J, Cooper M, Health M, Shehabi Y, Al-Bassam W, Hulley A, Whitehead C, Lowrey J, Gresha R, Walsham J, Meyer J, Harward M, Venz E, Williams P, Kurenda C, Smith K, Smith M, Garcia R, Barge D, Byrne D, Byrne K, Driscoll A, Fortune L, Janin P, Yarad E, Hammond N, Bass F, Ashelford A, Waterson S, Wedd S, McNamara R, Buhr H, Coles J, Schweikert S, Wibrow B, Rauniyar R, Myers E, Fysh E, Dawda A, Mevavala B, Litton E, Ferrier J, Nair P, Buscher H, Reynolds C, Santamaria J, Barbazza L, Homes J, Smith R, Murray L, Brailsford J, Forbes L, Maguire T, Mariappa V, Smith J, Simpson S, Maiden M, Bone A, Horton M, Salerno T, Sterba M, Geng W, Depuydt P, De Waele J, De Bus L, Fierens J, Bracke S, Reeve B, Dechert W, Chasse M, Carrier FM, Boumahni D, Benettaib F, Ghamraoui A, Bellemare D, Cloutier E, Francoeur C, Lamontagne F, D'Aragon F, Carbonneau E, Leblond J, Vazquez-Grande G, Marten N, Wilson M, Albert M, Serri K, Cavayas A, Duplaix M, Williams V, Rochwerg B, Karachi T, Oczkowski S, Centofanti J, Millen T, Duan E, Tsang J, Patterson L, English S, Watpool I, Porteous R, Miezitis S, McIntyre L, Brochard L, Burns K, Sandhu G, Khalid I, Binnie A, Powell E, McMillan A, Luk T, Aref N, Andric Z, Cviljevic S, Dimoti R, Zapalac M, Mirkovic G, Barsic B, Kutlesa M, Kotarski V, Vujaklija Brajkovic A, Babel J, Sever H, Dragija L, Kusan I, Vaara S, Pettila L, Heinonen J, Kuitunen A, Karlsson S, Vahtera A, Kiiski H, Ristimaki S, Azaiz A, Charron C, Godement M, Geri G, Vieillard-Baron A, Pourcine F, Monchi M, Luis D, Mercier R, Sagnier A, Verrier N, Caplin C, Siami S, Aparicio C, Vautier S, Jeblaoui A, Fartoukh M, Courtin L, Labbe V, Leparco C, Muller G, Nay MA, Kamel T, Benzekri D, Jacquier S, Mercier E, Chartier D, Salmon C, Dequin P, Schneider F, Morel G, L'Hotellier S, Badie J, Berdaguer FD, Malfroy S, Mezher C, Bourgoin C, Megarbane B, Voicu S, Deye N, Malissin I, Sutterlin L, Guitton C, Darreau C, Landais M, Chudeau N, Robert A, Moine P, Heming N, Maxime V, Bossard I, Nicholier TB, Colin G, Zinzoni V, Maquigneau N, Finn A, Kress G, Hoff U, Friedrich Hinrichs C, Nee J, Pletz M, Hagel S, Ankert J, Kolanos S, Bloos F, Petros S, Pasieka B, Kunz K, Appelt P, Schutze B, Kluge S, Nierhaus A, Jarczak D, Roedl K, Weismann D, Frey A, Klinikum Neukolln V, Reill L, Distler M, Maselli A, Belteczki J, Magyar I, Fazekas A, Kovacs S, Szoke V, Szigligeti G, Leszkoven J, Collins D, Breen P, Frohlich S, Whelan R, McNicholas B, Scully M, Casey S, Kernan M, Doran P, O'Dywer M, Smyth M, Hayes L, Hoiting O, Peters M, Rengers E, Evers M, Prinssen A, Bosch Ziekenhuis J, Simons K, Rozendaal W, Polderman F, de Jager P, Moviat M, Paling A, Salet A, Rademaker E, Peters AL, de Jonge E, Wigbers J, Guilder E, Butler M, Cowdrey KA, Newby L, Chen Y, Simmonds C, McConnochie R, Ritzema Carter J, Henderson S, Van Der Heyden K, Mehrtens J, Williams T, Kazemi A, Song R, Lai V, Girijadevi D, Everitt R, Russell R, Hacking D, Buehner U, Williams E, Browne T, Grimwade K, Goodson J, Keet O, Callender O, Martynoga R, Trask K, Butler A, Schischka L, Young C, Lesona E, Olatunji S, Robertson Y, Jose N, Amaro dos Santos Catorze T, de Lima Pereira TNA, Neves Pessoa LM, Castro Ferreira RM, Pereira Sousa Bastos JM, Aysel Florescu S, Stanciu D, Zaharia MF, Kosa AG, Codreanu D, Marabi Y, Al Qasim E, Moneer Hagazy M, Al Swaidan L, Arishi H, Munoz-Bermudez R, Marin-Corral J, Salazar Degracia A, Parrilla Gomez F, Mateo Lopez MI, Rodriguez Fernandez J, Carcel Fernandez S, Carmona Flores R, Leon Lopez R, de la Fuente Martos C, Allan A, Polgarova P, Farahi N, McWilliam S, Hawcutt D, Rad L, O'Malley L, Whitbread J, Kelsall O, Wild L, Thrush J, Wood H, Austin K, Donnelly A, Kelly M, O'Kane S, McClintock D, Warnock M, Johnston P, Gallagher LJ, Mc Goldrick C, Mc Master M, Strzelecka A, Jha R, Kalogirou M, Ellis C, Krishnamurthy V, Deelchand V, Silversides J, McGuigan P, Ward K, O'Neill A, Finn S, Phillips B, Mullan D, Oritz-Ruiz de Gordoa L, Thomas M, Sweet K, Grimmer L, Johnson R, Pinnell J, Robinson M, Gledhill L, Wood T, Morgan M, Cole J, Hill H, Davies M, Antcliffe D, Templeton M, Rojo R, Coghlan P, Smee J, Mackay E, Cort J, Whileman A, Spencer T, Spittle N, Kasipandian V, Patel A, Allibone S, Genetu RM, Ramali M, Ghosh A, Bamford P, London E, Cawley K, Faulkner M, Jeffrey H, Smith T, Brewer C, Gregory J, Limb J, Cowton A, O'Brien J, Nikitas N, Wells C, Lankester L, Pulletz M, Williams P, Birch J, Wiseman S, Horton S, Alegria A, Turki S, Elsefi T, Crisp N, Allen L, McCullagh I, Robinson P, Hays C, Babio-Galan M, Stevenson H, Khare D, Pinder M, Selvamoni S, Gopinath A, Pugh R, Menzies D, Mackay C, Allan E, Davies G, Puxty K, McCue C, Cathcart S, Hickey N, Ireland J, Yusuff H, Isgro G, Brightling C, Bourne M, Craner M, Watters M, Prout R, Davies L, Pegler S, Kyeremeh L, Arbane G, Wilson K, Gomm L, Francia F, Brett S, Sousa Arias S, Elin Hall R, Budd J, Small C, Birch J, Collins E, Henning J, Bonner S, Hugill K, Cirstea E, Wilkinson D, Karlikowski M, Sutherland H, Wilhelmsen E, Woods J, North J, Sundaran D, Hollos L, Coburn S, Walsh J, Turns M, Hopkins P, Smith J, Noble H, Depante MT, Clarey E, Laha S, Verlander M, Williams A, Huckle A, Hall A, Cooke J, Gardiner-Hill C, Maloney C, Qureshi H, Flint N, Nicholson S, Southin S, Nicholson A, Borgatta B, Turner-Bone I, Reddy A, Wilding L, Chamara Warnapura L, Agno Sathianathan R, Golden D, Hart C, Jones J, Bannard-Smith J, Henry J, Birchall K, Pomeroy F, Quayle R, Makowski A, Misztal B, Ahmed I, KyereDiabour T, Naiker K, Stewart R, Mwaura E, Mew L, Wren L, Willams F, Innes R, Doble P, Hutter J, Shovelton C, Plumb B, Szakmany T, Hamlyn V, Hawkins N, Lewis S, Dell A, Gopal S, Ganguly S, Smallwood A, Harris N, Metherell S, Lazaro JM, Newman T, Fletcher S, Nortje J, Fottrell-Gould D, Randell G, Zaman M, Elmahi E, Jones A, Hall K, Mills G, Ryalls K, Bowler H, Sall J, Bourne R, Borrill Z, Duncan T, Lamb T, Shaw J, Fox C, Moreno Cuesta J, Xavier K, Purohit D, Elhassan M, Bakthavatsalam D, Rowland M, Hutton P, Bashyal A, Davidson N, Hird C, Chhablani M, Phalod G, Kirkby A, Archer S, Netherton K, Reschreiter H, Camsooksai J, Patch S, Jenkins S, Pogson D, Rose S, Daly Z, Brimfield L, Claridge H, Parekh D, Bergin C, Bates M, Dasgin J, McGhee C, Sim M, Hay SK, Henderson S, Phull MK, Zaidi A, Pogreban T, Rosaroso LP, Harvey D, Lowe B, Meredith M, Ryan L, Hormis A, Walker R, Collier D, Kimpton S, Oakley S, Rooney K, Rodden N, Hughes E, Thomson N, McGlynn D, Walden A, Jacques N, Coles H, Tilney E, Vowell E, Schuster-Bruce M, Pitts S, Miln R, Purandare L, Vamplew L, Spivey M, Bean S, Burt K, Moore L, Day C, Gibson C, Gordon E, Zitter L, Keenan S, Baker E, Cherian S, Cutler S, Roynon-Reed A, Harrington K, Raithatha A, Bauchmuller K, Ahmad N, Grecu I, Trodd D, Martin J, Wrey Brown C, Arias AM, Craven T, Hope D, Singleton J, Clark S, Rae N, Welters I, Hamilton DO, Williams K, Waugh V, Shaw D, Puthucheary Z, Martin T, Santos F, Uddin R, Somerville A, Tatham KC, Jhanji S, Black E, Dela Rosa A, Howle R, Tully R, Drummond A, Dearden J, Philbin J, Munt S, Vuylsteke A, Chan C, Victor S, Matsa R, Gellamucho M, Creagh-Brown B, Tooley J, Montague L, De Beaux F, Bullman L, Kersiake I, Demetriou C, Mitchard S, Ramos L, White K, Donnison P, Johns M, Casey R, Mattocks L, Salisbury S, Dark P, Claxton A, McLachlan D, Slevin K, Lee S, Hulme J, Joseph S, Kinney F, Senya HJ, Oborska A, Kayani A, Hadebe B, Orath Prabakaran R, Nichols L, Thomas M, Worner R, Faulkner B, Gendall E, Hayes K, Hamilton-Davies C, Chan C, Mfuko C, Abbass H, Mandadapu V, Leaver S, Forton D, Patel K, Paramasivam E, Powell M, Gould R, Wilby E, Howcroft C, Banach D, Fernandez de Pinedo Artaraz Z, Cabreros L, White I, Croft M, Holland N, Pereira R, Zaki A, Johnson D, Jackson M, Garrard H, Juhaz V, Roy A, Rostron A, Woods L, Cornell S, Pillai S, Harford R, Rees T, Ivatt H, Sundara Raman A, Davey M, Lee K, Barber R, Chablani M, Brohi F, Jagannathan V, Clark M, Purvis S, Wetherill B, Dushianthan A, Cusack R, de Courcy-Golder K, Smith S, Jackson S, Attwood B, Parsons P, Page V, Zhao XB, Oza D, Rhodes J, Anderson T, Morris S, Xia Le Tai C, Thomas A, Keen A, Digby S, Cowley N, Wild L, Southern D, Reddy H, Campbell A, Watkins C, Smuts S, Touma O, Barnes N, Alexander P, Felton T, Ferguson S, Sellers K, Bradley-Potts J, Yates D, Birkinshaw I, Kell K, Marshall N, Carr-Knott L, Summers C. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022. PubMed 32876697 ↗
  • Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, Thompson BT, Ancukiewicz M; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006 Apr 20;354(16):1671-84. doi: 10.1056/NEJMoa051693. PubMed 16625008 ↗
  • Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, Aguilar G, Alba F, Gonzalez-Higueras E, Conesa LA, Martin-Rodriguez C, Diaz-Dominguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Anon JM, Fernandez RL, Gonzalez-Martin JM; dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020 Mar;8(3):267-276. doi: 10.1016/S2213-2600(19)30417-5. Epub 2020 Feb 7. PubMed 32043986 ↗
  • Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior GFS, Morais DC, Zung S, Machado FR, Azevedo LCP; COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021. PubMed 32876695 ↗
  • RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. PubMed 32678530 ↗
  • Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, Carcillo JA, Correa R, Drover K, Esper AM, Gershengorn HB, Hammond NE, Jayaprakash N, Menon K, Nazer L, Pitre T, Qasim ZA, Russell JA, Santos AP, Sarwal A, Spencer-Segal J, Tilouche N, Annane D, Pastores SM. 2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia. Crit Care Med. 2024 May 1;52(5):e219-e233. doi: 10.1097/CCM.0000000000006172. Epub 2024 Jan 19. PubMed 38240492 ↗
  • Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77. doi: 10.1056/NEJMoa010307. PubMed 11794169 ↗
  • Munroe ES, Co IN, Douglas I, Hyzy R, Khan A, Nelson K, Park PK, Peltan ID, Rice TW, Seelye S, Self WH, Shapiro NI, Prescott HC; NHLBI PETAL Network. Peripheral Vasopressor Use in Early Sepsis-Induced Hypotension. JAMA Netw Open. 2025 Aug 1;8(8):e2529148. doi: 10.1001/jamanetworkopen.2025.29148. PubMed 40864467 ↗
  • Kalimouttou A, Kennedy JN, Feng J, Singh H, Saria S, Angus DC, Seymour CW, Pirracchio R. Optimal Vasopressin Initiation in Septic Shock: The OVISS Reinforcement Learning Study. JAMA. 2025 May 20;333(19):1688-1698. doi: 10.1001/jama.2025.3046. PubMed 40098600 ↗
  • Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators; Cavalcanti AB, Suzumura EA, Laranjeira LN, Paisani DM, Damiani LP, Guimaraes HP, Romano ER, Regenga MM, Taniguchi LNT, Teixeira C, Pinheiro de Oliveira R, Machado FR, Diaz-Quijano FA, Filho MSA, Maia IS, Caser EB, Filho WO, Borges MC, Martins PA, Matsui M, Ospina-Tascon GA, Giancursi TS, Giraldo-Ramirez ND, Vieira SRR, Assef MDGPL, Hasan MS, Szczeklik W, Rios F, Amato MBP, Berwanger O, Ribeiro de Carvalho CR. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2017 Oct 10;318(14):1335-1345. doi: 10.1001/jama.2017.14171. PubMed 28973363 ↗
  • Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159-68. doi: 10.1056/NEJMoa1214103. Epub 2013 May 20. PubMed 23688302 ↗
  • Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guerin C, Prat G, Morange S, Roch A; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372. PubMed 20843245 ↗
  • Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8. doi: 10.1056/NEJM200005043421801. PubMed 10793162 ↗
  • Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993 Oct 15;119(8):771-8. doi: 10.7326/0003-4819-119-8-199310150-00001. PubMed 8379598 ↗
  • Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP; NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005 Jan;33(1):1-6; discussion 230-2. doi: 10.1097/01.ccm.0000149854.61192.dc. PubMed 15644641 ↗
  • Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014 Aug;2(8):611-20. doi: 10.1016/S2213-2600(14)70097-9. Epub 2014 May 19. PubMed 24853585 ↗
  • Sinha P, Churpek MM, Calfee CS. Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data. Am J Respir Crit Care Med. 2020 Oct 1;202(7):996-1004. doi: 10.1164/rccm.202002-0347OC. PubMed 32551817 ↗
  • Sinha P, Furfaro D, Cummings MJ, Abrams D, Delucchi K, Maddali MV, He J, Thompson A, Murn M, Fountain J, Rosen A, Robbins-Juarez SY, Adan MA, Satish T, Madhavan M, Gupta A, Lyashchenko AK, Agerstrand C, Yip NH, Burkart KM, Beitler JR, Baldwin MR, Calfee CS, Brodie D, O'Donnell MR. Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids. Am J Respir Crit Care Med. 2021 Dec 1;204(11):1274-1285. doi: 10.1164/rccm.202105-1302OC. PubMed 34543591 ↗
  • Grasselli G, Calfee CS, Camporota L, Poole D, Amato MBP, Antonelli M, Arabi YM, Baroncelli F, Beitler JR, Bellani G, Bellingan G, Blackwood B, Bos LDJ, Brochard L, Brodie D, Burns KEA, Combes A, D'Arrigo S, De Backer D, Demoule A, Einav S, Fan E, Ferguson ND, Frat JP, Gattinoni L, Guerin C, Herridge MS, Hodgson C, Hough CL, Jaber S, Juffermans NP, Karagiannidis C, Kesecioglu J, Kwizera A, Laffey JG, Mancebo J, Matthay MA, McAuley DF, Mercat A, Meyer NJ, Moss M, Munshi L, Myatra SN, Ng Gong M, Papazian L, Patel BK, Pellegrini M, Perner A, Pesenti A, Piquilloud L, Qiu H, Ranieri MV, Riviello E, Slutsky AS, Stapleton RD, Summers C, Thompson TB, Valente Barbas CS, Villar J, Ware LB, Weiss B, Zampieri FG, Azoulay E, Cecconi M; European Society of Intensive Care Medicine Taskforce on ARDS. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023 Jul;49(7):727-759. doi: 10.1007/s00134-023-07050-7. Epub 2023 Jun 16. PubMed 37326646 ↗
  • Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Moller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov;47(11):1181-1247. doi: 10.1007/s00134-021-06506-y. Epub 2021 Oct 2. No abstract available. PubMed 34599691 ↗
  • Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002. PubMed 11445675 ↗
  • Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291. PubMed 26903337 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 43 non-industry phase 2 interventional studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 35. This study's planned 23 months is below that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Jun 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added
Show 10 added (10 China)
  • Peking University People's Hospital · Beijing, China
  • Zhangzhou Hospital Affiliated to Fujian Medical University · Zhangzhou, China
  • Dongguan Tungwah Hospital · Dongguan, China
  • Guangdong Provincial Hospital of Chinese Medicine · Guangzhou, China
  • Cangzhou Central Hospital · Cangzhou, China
  • The First Affiliated Hospital, Jiangxi Medical College · Nanchang, China
  • The Second Hospital of Shanxi Medical University · Taiyuan, China
  • People's Hospital of Xinjiang Uygur Autonomous Region · Ürümqi, China
  • Qujing Central Hospital of Yunnan Province · Qujing, China
  • Zhejiang Provincial People's Hospital · Hangzhou, China
Nov 18, 2026
Eligibility
2 inclusion criteria edited, 4 added, 9 removed; 6 exclusion criteria edited, 4 added, 8 removed
What changed in the criteria
Inclusion criteria
  • RemovedParticipants must meet all of the following criteria:
  • RemovedDiagnosis of acute respiratory distress syndrome (ARDS) or sepsis.
  • RemovedARDS will be defined according to standard criteria:
  • Removedacute onset within 1 week of a known clinical insult or new/worsening respiratory symptoms;
  • Removedbilateral pulmonary opacities on chest imaging (X-ray or CT) or bilateral B-lines and/or consolidation on lung ultrasound, not fully explained by effusion, atelectasis, or nodules;
  • Removedrespiratory failure not fully explained by cardiac failure or fluid overload;
  • Removedhypoxemia defined as PaO₂/FiO₂ ≤300 mmHg or SpO₂/FiO₂ ≤315 (with SpO₂ ≤97%) under a minimum positive end-expiratory pressure (PEEP) of 5 cmH₂O.
  • AddedOnset of ARDS and/or sepsis within 72 hours.
  • AddedARDS is defined according to the Berlin definition: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by pleural effusions, lobar or lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload; and PaO2/FiO2 ≤300 mmHg with PEEP ≥ 5 cm H2O.
  • EditedSepsis will beis defined according to the Sepsis-3 criteria as suspected or confirmed infection withaccompanied by an acute increase in SOFA score of ≥ 2 points, assuming a baseline SOFA score of 0 in patients without known prior organ dysfunction attributable to infection.
  • RemovedSepsis-associated ARDS will be defined as ARDS occurring in patients with sepsis.
  • AddedRequirement for invasive mechanical ventilation.
  • Edited3. Receiving invasive mechanical ventilation. 4. Admission to the intensive care unit (ICU). 5. Hyperinflammatory phenotype, defined as a predicted probability ≥ 0.550 using a validated AIthe clinical classifier based on clinical data.
  • Removed6. Randomization within 72 hours of ARDS or sepsis onset. 7. Provision of written informed consent by the patient or their legally authorized representative.
  • AddedWritten informed consent provided by the participant or a legally authorised representative.
Exclusion criteria
  • RemovedParticipants meeting any of the following criteria will be excluded:
  • EditedRequirement for high-doseHigh vasopressor supportrequirement, defined as a norepinephrine-equivalent dose (NEE) ≥0.5 μg/kg/min or epinephrine ≥ 0.25 μg/kg/min.
  • RemovedPost-cardiac surgery patients (e.g., coronary artery bypass grafting or valve replacement).
  • RemovedConditions requiring systemic corticosteroid therapy exceeding 1 mg/kg methylprednisolone or an equivalent dose (e.g., acute asthma exacerbation, acute exacerbation of chronic obstructive pulmonary disease, or autoimmune diseases).
  • RemovedLong-term systemic corticosteroid use within the past 6 months.
  • AddedSystemic corticosteroid exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any immunosuppressive agent within the same period.[16]
  • EditedHistory of solid Solid-organ transplantation or allogeneic hematopoietic stem -cell transplantation.
  • AddedSevere congenital or acquired immunodeficiency, including HIV infection.
  • EditedAdvancedBrain death, expected death within 24 hours, or advanced malignancy or other end-stage disease with an expected survivala life expectancy of less than 6 months, or anticipated death within 24 hours.
  • RemovedKnown hypersensitivity to methylprednisolone, including but not limited to urticaria, eczema, angioedema, bronchospasm, or anaphylaxis.
  • EditedDoA do-not-resuscitate (DNR) ordersorder or withdrawal ofa decision to withdraw or withhold life-sustaining treatment.
  • EditedActive lifeLife-threatening active fungal infection or active tuberculosis.
  • RemovedNeuromuscular disorders affecting spontaneous respiration.
  • RemovedSevere inherited or acquired immunodeficiency (e.g., human immunodeficiency virus infection, chronic granulomatous disease, or severe combined immunodeficiency).
  • AddedKnown hypersensitivity to corticosteroids.
  • RemovedBrain death.
  • AddedNeuromuscular disease that substantially impairs spontaneous breathing.
  • EditedAny other clinical condition that, in the opinion of the treating physician or investigator, would makemakes participation in the study inappropriate.
Nov 18, 2026
Secondary outcomes
3 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameother outcomeProbability of transition from hyperinflammatory to hypoinflammatory phenotypeAt Days 4, 7, 9, and 15 after randomization → At Days 1,4, 7, 9, and 15 after randomization
  • Time frameother outcomeBiomarker levels after randomizationAt Days 4, 7, 9, and 15 after randomization → At Days 1,4, 7, 9, and 15 after randomization
  • Time frameother outcomeVasoactive-Inotropic Score (VIS)At Days 4, 7, 9, and 15 after randomization → At Days 1,4, 7, 9, and 15 after randomization
  • Descriptionother outcomeBiomarker levels after randomization: how it is measured was reworded
  • Descriptionother outcomeProbability of transition from hyperinflammatory to hypoinflammatory phenotype: how it is measured was reworded
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    10 sites added
    Show 10 added (10 China)
    • Peking University People's Hospital · Beijing, China
    • Zhangzhou Hospital Affiliated to Fujian Medical University · Zhangzhou, China
    • Dongguan Tungwah Hospital · Dongguan, China
    • Guangdong Provincial Hospital of Chinese Medicine · Guangzhou, China
    • Cangzhou Central Hospital · Cangzhou, China
    • The First Affiliated Hospital, Jiangxi Medical College · Nanchang, China
    • The Second Hospital of Shanxi Medical University · Taiyuan, China
    • People's Hospital of Xinjiang Uygur Autonomous Region · Ürümqi, China
    • Qujing Central Hospital of Yunnan Province · Qujing, China
    • Zhejiang Provincial People's Hospital · Hangzhou, China
    Eligibility 2 inclusion criteria edited, 4 added, 9 removed; 6 exclusion criteria edited, 4 added, 8 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedParticipants must meet all of the following criteria:
    • RemovedDiagnosis of acute respiratory distress syndrome (ARDS) or sepsis.
    • RemovedARDS will be defined according to standard criteria:
    • Removedacute onset within 1 week of a known clinical insult or new/worsening respiratory symptoms;
    • Removedbilateral pulmonary opacities on chest imaging (X-ray or CT) or bilateral B-lines and/or consolidation on lung ultrasound, not fully explained by effusion, atelectasis, or nodules;
    • Removedrespiratory failure not fully explained by cardiac failure or fluid overload;
    • Removedhypoxemia defined as PaO₂/FiO₂ ≤300 mmHg or SpO₂/FiO₂ ≤315 (with SpO₂ ≤97%) under a minimum positive end-expiratory pressure (PEEP) of 5 cmH₂O.
    • AddedOnset of ARDS and/or sepsis within 72 hours.
    • AddedARDS is defined according to the Berlin definition: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by pleural effusions, lobar or lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload; and PaO2/FiO2 ≤300 mmHg with PEEP ≥ 5 cm H2O.
    • EditedSepsis will beis defined according to the Sepsis-3 criteria as suspected or confirmed infection withaccompanied by an acute increase in SOFA score of ≥ 2 points, assuming a baseline SOFA score of 0 in patients without known prior organ dysfunction attributable to infection.
    • RemovedSepsis-associated ARDS will be defined as ARDS occurring in patients with sepsis.
    • AddedRequirement for invasive mechanical ventilation.
    • Edited3. Receiving invasive mechanical ventilation. 4. Admission to the intensive care unit (ICU). 5. Hyperinflammatory phenotype, defined as a predicted probability ≥ 0.550 using a validated AIthe clinical classifier based on clinical data.
    • Removed6. Randomization within 72 hours of ARDS or sepsis onset. 7. Provision of written informed consent by the patient or their legally authorized representative.
    • AddedWritten informed consent provided by the participant or a legally authorised representative.
    Exclusion criteria
    • RemovedParticipants meeting any of the following criteria will be excluded:
    • EditedRequirement for high-doseHigh vasopressor supportrequirement, defined as a norepinephrine-equivalent dose (NEE) ≥0.5 μg/kg/min or epinephrine ≥ 0.25 μg/kg/min.
    • RemovedPost-cardiac surgery patients (e.g., coronary artery bypass grafting or valve replacement).
    • RemovedConditions requiring systemic corticosteroid therapy exceeding 1 mg/kg methylprednisolone or an equivalent dose (e.g., acute asthma exacerbation, acute exacerbation of chronic obstructive pulmonary disease, or autoimmune diseases).
    • RemovedLong-term systemic corticosteroid use within the past 6 months.
    • AddedSystemic corticosteroid exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any immunosuppressive agent within the same period.[16]
    • EditedHistory of solid Solid-organ transplantation or allogeneic hematopoietic stem -cell transplantation.
    • AddedSevere congenital or acquired immunodeficiency, including HIV infection.
    • EditedAdvancedBrain death, expected death within 24 hours, or advanced malignancy or other end-stage disease with an expected survivala life expectancy of less than 6 months, or anticipated death within 24 hours.
    • RemovedKnown hypersensitivity to methylprednisolone, including but not limited to urticaria, eczema, angioedema, bronchospasm, or anaphylaxis.
    • EditedDoA do-not-resuscitate (DNR) ordersorder or withdrawal ofa decision to withdraw or withhold life-sustaining treatment.
    • EditedActive lifeLife-threatening active fungal infection or active tuberculosis.
    • RemovedNeuromuscular disorders affecting spontaneous respiration.
    • RemovedSevere inherited or acquired immunodeficiency (e.g., human immunodeficiency virus infection, chronic granulomatous disease, or severe combined immunodeficiency).
    • AddedKnown hypersensitivity to corticosteroids.
    • RemovedBrain death.
    • AddedNeuromuscular disease that substantially impairs spontaneous breathing.
    • EditedAny other clinical condition that, in the opinion of the treating physician or investigator, would makemakes participation in the study inappropriate.
    Secondary outcomes 3 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameother outcomeProbability of transition from hyperinflammatory to hypoinflammatory phenotypeAt Days 4, 7, 9, and 15 after randomization → At Days 1,4, 7, 9, and 15 after randomization
    • Time frameother outcomeBiomarker levels after randomizationAt Days 4, 7, 9, and 15 after randomization → At Days 1,4, 7, 9, and 15 after randomization
    • Time frameother outcomeVasoactive-Inotropic Score (VIS)At Days 4, 7, 9, and 15 after randomization → At Days 1,4, 7, 9, and 15 after randomization
    • Descriptionother outcomeBiomarker levels after randomization: how it is measured was reworded
    • Descriptionother outcomeProbability of transition from hyperinflammatory to hypoinflammatory phenotype: how it is measured was reworded
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07511582
Lead sponsor
Bin Du
Responsible party
Bin Du (Senior Consultant Physician; Professor, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Apr 6, 2026
Start date
Apr 15, 2026
Primary completion
Apr 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Bin Du
Contact
dubin98@gmail.com
+86 6916 5643

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone

Start the discussion